Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

The Market Herald10-04

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. Orphan drug status is that classification awarded to drugs by the FDA ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472729386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-04 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472729386","market":"us","top_or_hot":-1,"title":"Neurotech knocked back by FDA as agency declares target condition not rare enough for special status","media":"The Market Herald","content":"<div>\n<p>Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. \nOrphan drug status is that classification awarded to drugs by the FDA ...</p>\n\n<a href=\"https://themarketonline.com.au/neurotech-knocked-back-by-fda-as-agency-declares-target-condition-not-rare-enough-for-special-status-2024-10-04/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurotech knocked back by FDA as agency declares target condition not rare enough for special status</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurotech knocked back by FDA as agency declares target condition not rare enough for special status\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-04 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/neurotech-knocked-back-by-fda-as-agency-declares-target-condition-not-rare-enough-for-special-status-2024-10-04/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. \nOrphan drug status is that classification awarded to drugs by the FDA ...</p>\n\n<a href=\"https://themarketonline.com.au/neurotech-knocked-back-by-fda-as-agency-declares-target-condition-not-rare-enough-for-special-status-2024-10-04/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTI.AU","symbol_name":"NEUROTECH INTERNATIONAL LTD","start_time":0,"source_url":"https://themarketonline.com.au/neurotech-knocked-back-by-fda-as-agency-declares-target-condition-not-rare-enough-for-special-status-2024-10-04/","article_id":"2472729386","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472729386","pubTimestamp":1727999820,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Neurotech International  has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status.Orphan drug status is that classification awarded to drugs by the FDA for, often, rare diseases. Companies can access tax credits for running trials, see less fees overall, and in some cases, the FDA will award market exclusivity for seven years.However, on Friday, Neurotech confirmed the FDA has failed to deem the company’s target conditions – Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections  and Paediatric Acute- Onset Neuropsychiatric Syndrome  respectively – as being rare enough.PANDAS is, for its part, what it sounds like – often referring to the development of obsessive compulsive tic symptoms following an infection of strep throat. The condition is regarded as an autoimmune issue.The US-based National Institute of Mental Health  writes on its webpage for the condition that certain natural antibodies a human being prod","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTI.AU":"NEUROTECH INTERNATIONAL LTD","BK7007":"医疗保健设备"},"translate_title":"FDA宣布目标条件不够罕见，无法获得特殊地位，Neurotech遭到FDA打击","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTI.AU":1},"content_text":"Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. \nOrphan drug status is that classification awarded to drugs by the FDA for, often, rare diseases. Companies can access tax credits for running trials, see less fees overall, and in some cases, the FDA will award market exclusivity for seven years. \nHowever, on Friday, Neurotech confirmed the FDA has failed to deem the company’s target conditions – Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute- Onset Neuropsychiatric Syndrome (PANS) respectively – as being rare enough. \nPANDAS is, for its part, what it sounds like – often referring to the development of obsessive compulsive tic symptoms following an infection of strep throat. The condition is regarded as an autoimmune issue.\nThe US-based National Institute of Mental Health (NIH) writes on its webpage for the condition that certain natural antibodies a human being produces to battle off strep can ‘malfunction’ and enter the brain where they can cause OCD symptoms – or worsen that underlying condition. \nThe FDA did not challenge that the condition exists, by any means. But it did take issue with the second condition, PANS.\nAll in all, the US-based medicines regulator isn’t convinced there’s enough evidence to suggest that PANS is a standalone condition compared to PANDA – which means the company doesn’t have two rare conditions to treat, just the one. \nAnd when it comes to establishing what is rare and what isn’t, the FDA is further unsure Neurotech’s data is the most reliable when it points to prevalence rates. NTI points to a 1-in-200 prevalence in children across the USA, but on Friday, the FDA effectively asked for a please explain.\nNeurotech now has 12 months to address a reply to the regulator and provide supporting evidence. The company wrote on Friday it is, in layman’s terms, making up its mind on what to do.\nNTI last traded at 5.8cps. \nJoin the discussion: See what HotCopper users are saying about Neurotech and be part of the conversations that move the markets.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472729386"}